.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA03_Melphalan.Melphalan

Information

Melphalan is an alkylating agent used in the treatment of multiple myeloma and ovarian cancer. It works by cross-linking DNA, thus inhibiting DNA and RNA synthesis and leading to cell death. It is still approved and in clinical use, particularly for hematological malignancies.

Pharmacokinetics

Pharmacokinetic parameters derived from adult patients with multiple myeloma receiving intravenous melphalan for conditioning therapy prior to stem cell transplantation.

References

1. Nath, CE, et al., & Earl, J (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British journal of clinical pharmacology 69(5) 484–497. DOI:10.1111/j.1365-2125.2010.03638.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20573084

2. Nath, CE, et al., & Earl, JW (2007). Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. British journal of clinical pharmacology 64(2) 151–164. DOI:10.1111/j.1365-2125.2007.02862.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17324241

3. Mougenot, P, et al., & Bressolle, F (2004). Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer chemotherapy and pharmacology 53(6) 503–512. DOI:10.1007/s00280-003-0761-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15007638

Revisions

• 06/2025 initial generated model